By Sean Marshall
Good news from the FDA this week. A press release from U.S. Food and Drug association has outlined what is to come from them to combat sickle cell disease in the future. According to the documents found on their site the FDA plans on dealing with sickle cell disease in all its stages, at least according to one of their spokespeople M.D. Anna T. Farrell.“These potential treatments are in different stages of development, including early and late clinical trials,” explained Farrell
The plan is for the FDA to grant companies the ability to what the press released called “a “fast track” designation.” This is where the drug companies and their sponsor are allowed early and more frequent interactions with the FDA to bring up any and both ethical and health issues concerns as well as any problems with developing, drug testing and the initial trials. It was said by Farrell “the purpose of these consultations is to bring the new product to market faster.”
It was also mentioned that “orphan products” would be designed. These are products that are intended to treat rare diseases affecting 200,00 individuals in the U.S.A per year.
If you would lie to learn more about what the FDA is doing follow the link below:
If you have any comments questions or concerns email us at email@example.com
This section is solely to let our Sickle Soldiers tell their story trials & tribulations alongside things they feel are wrong in the Sickle Cell Community